🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

183+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 183 recruiting trials for “hepatocellular-carcinoma

NARecruitingNCT06190665

DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC

👨‍⚕️ Gao-Jun Teng, Zhongda Hospital📍 2 sites📅 Started Dec 2023View details ↗
RecruitingNCT05705219

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

👨‍⚕️ Ahmed El Kaffas, PhD, University of California, San Diego📍 3 sites📅 Started Dec 2023View details ↗
Phase 2RecruitingNCT06034977

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

👨‍⚕️ Wei-Ting Chen, MD, Chang Gung Memorial Hospital📍 1 site📅 Started Dec 2023View details ↗
Phase 1RecruitingNCT06010875

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

👨‍⚕️ Fei Li, M.D, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Nov 2023View details ↗
RecruitingNCT06117891

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

🏥 Bayer📍 20 sites📅 Started Nov 2023View details ↗
Phase 1, PHASE2RecruitingNCT05808608

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

👨‍⚕️ Hao Zeng, Professor, West China Hospital📍 1 site📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT06133062

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

🏥 Chang Gung Memorial Hospital📍 1 site📅 Started Nov 2023View details ↗
Enrolling by InvitationNCT05429190

Validation of SMS Protocol for HCC Screening in High-risk Patients

👨‍⚕️ Prof. Dr. de Man, Erasmus Medical Center📍 6 sites📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT05440864

Durvalumab and Tremelimumab in Resectable HCC

👨‍⚕️ Gonzalo Sapisochin, MD, Univeristy Health Network📍 3 sites📅 Started Oct 2023View details ↗
NARecruitingNCT06101290

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

👨‍⚕️ Mamta Parikh, MD, MS, University of California, Davis📍 1 site📅 Started Oct 2023View details ↗
RecruitingNCT06391879

Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma

👨‍⚕️ Kan Gong, Peking University First Hospital📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT05263830

Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy

👨‍⚕️ Manon ALLAIRE, Dr, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Sep 2023View details ↗
RecruitingNCT06036563

Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing

🏥 Air Force Military Medical University, China📍 8 sites📅 Started Sep 2023View details ↗
RecruitingNCT06060769

Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging

👨‍⚕️ Yaqin Zhang, MD, Ph.D, Fifth Affiliated Hospital, Sun Yat-Sen University📍 1 site📅 Started Sep 2023View details ↗
Phase 4RecruitingNCT07132515

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

🏥 Mansoura University📍 1 site📅 Started Aug 2023View details ↗
RecruitingNCT06076538

PET/MR for Characterization of Renal Masses (RMs)

👨‍⚕️ Ivan Pedrosa, MD, PhD, University of Texas Southwestern Medical Center📍 1 site📅 Started Aug 2023View details ↗
Phase 2RecruitingNCT05451043

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

🏥 AHS Cancer Control Alberta📍 1 site📅 Started Jul 2023View details ↗
Phase 1RecruitingNCT05868174

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

🏥 Telix Pharmaceuticals (Innovations) Pty Limited📍 5 sites📅 Started May 2023View details ↗
Phase 3RecruitingNCT05862337

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

🏥 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.📍 67 sites📅 Started May 2023View details ↗
Phase 2RecruitingNCT06370065

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

🏥 Tianjin Medical University Cancer Institute and Hospital📍 1 site📅 Started Apr 2023View details ↗
← PreviousPage 6 of 10Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →